HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure.

AbstractOBJECTIVE:
The artificial liver support system (ALSS) is used frequently as a first-line treatment for hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). This study aims to compare the therapeutic efficacy of double plasma molecular adsorption system (DPMAS) with sequential half-dose plasma exchange (PE) (DPMAS+PE) and full-dose PE in patients with HBV-ACLF.
METHODS:
A total of 131 hospitalized patients who were diagnosed with HBV-ACLF and underwent DPMAS+PE or PE were retrospectively analyzed. According to the treatment methods used, they were divided into PE group (n = 77) and DPMAS+PE group (n = 54). The main evaluation indexes included the change of liver function and the 28-days liver transplant-free survival rates after the different treatments.
RESULTS:
There were no significant differences on severity of illness between PE group and DPMAS+PE group (P > 0.05). The total bilirubin (TBIL) levels immediately after treatment, and at 24 and 72 hours after treatment were markedly decreased in DPMAS+PE group than that in PE group (52.3 ± 9.4% vs 42.3 ± 7.2%, P < 0.05; 24.2 ± 10.0% vs 13.5 ± 13.0%, P < 0.05; 24.8 ± 13.1% vs 14.9 ± 14.9%, P < 0.05; respectively). The 28-days survival rates was 62.3% and 72.2% in PE and DPMAS+PE groups (P = 0.146). Furthermore, the 28-days survival rates were significantly higher in DPMAS+PE group than that in PE group (57.4% vs 41.7%, P = 0.043) in the intermediate-advanced stage patients.
CONCLUSION:
Compared with PE alone, DPMAS+PE might more effectively improve temporary TBIL in ACLF patients, and improve the 28-days survival rates in HBV-ACLF patients with intermediate-advanced stage. Therefore, DPMAS+PE may be an available ALSS treatment for HBV-ACLF patients.
AuthorsJia Yao, Shuang Li, Li Zhou, Lei Luo, Lili Yuan, Zhongping Duan, Jun Xu, Yu Chen
JournalJournal of clinical apheresis (J Clin Apher) Vol. 34 Issue 4 Pg. 392-398 (Aug 2019) ISSN: 1098-1101 [Electronic] United States
PMID30758886 (Publication Type: Journal Article)
Copyright© 2019 The Authors. Journal of Clinical Apheresis published by Wiley Periodicals, Inc.
Chemical References
  • Bilirubin
Topics
  • Acute-On-Chronic Liver Failure (mortality, therapy, virology)
  • Adsorption
  • Bilirubin (analysis)
  • Female
  • Hepatitis B virus
  • Humans
  • Liver (physiology)
  • Liver Transplantation
  • Male
  • Middle Aged
  • Plasma Exchange (methods)
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: